We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Genetics and management of inherited cancer predisposition 1
- Prof. Joshua Schiffman
-
2. Genetics and management of inherited cancer predisposition 2
- Prof. Joshua Schiffman
-
3. The cytogenetics of childhood acute leukemia
- Dr. Susana C. Raimondi
-
4. Chromosome translocations and cancer
- Prof. Felix Mitelman
-
5. Acute myeloid leukemia: genetics, prognosis and treatments
- Prof. Stephen Nimer
-
6. Genetic abnormalities in acute lymphoblastic leukemia
- Prof. Ching Hon Pui
-
7. Molecular genetics of non-Hodgkin lymphoma
- Prof. Jude Fitzgibbon
-
8. Genetics of breast and ovarian cancer
- Prof. Jeffrey Weitzel
-
9. The genetics and genomics of familial renal carcinoma
- Prof. Eamonn Maher
-
10. Genomics of lung cancer
- Prof. Ramaswamy Govindan
-
11. The genetics of glioblastoma
- Dr. Hai Yan
-
12. Genetics of tumor metastasis 1
- Prof. Robert Weinberg
-
13. Genetics of tumor metastasis 2
- Prof. Robert Weinberg
-
14. CML: genetic paradigm of targeted therapy 1
- Prof. Michael W. Deininger
-
15. CML: genetic paradigm of targeted therapy 2
- Prof. Michael W. Deininger
-
16. The non-coding RNA revolution in the cancer society
- Prof. George Calin
-
17. Role of molecular markers in guiding therapy in cancer
- Prof. Joe Duffy
-
18. Functional cancer genomics
- Prof. Roderick Beijersbergen
-
19. Pharmacogenomics in cancer therapy
- Prof. Sharon Marsh
Printable Handouts
Navigable Slide Index
- Introduction
- Glioma research
- Talk outline
- Classifications of glioma
- Glioma distribution by histologic subtype
- Median age at diagnosis of glioma by subtype
- Glioma patient survival
- Use of genomics in glioma research
- 3 key points in glioma research
- Genomic analysis of human glioblastoma
- IDH1 and IDH2 mutations in gliomas
- IDH1 and IDH2: isocitrate dehydrogenases
- Hotspots of IDH1 or IDH2
- Mutant IDH1 enzyme activity and epigenetic
- Glioma diagnosis: a major challenge
- Observer reliability in histological grading
- Genomic based diagnosis (WHO)
- Genetic profile and prediction of treatment efficacy
- IDH1/TERT mutations: glioma patient survival
- Cutting-edge findings in glioma genomic research
- Current alterations in glioblastoma
- Genetics of glioblastoma: past findings resources
- Current updates in the genomics of glioblastoma
- Frequency of TERT promoter mutations
- Mutation distribution of IDH1/2 and TERT promoter
- Updates in the genetic classification of gliomas
- Summary materials and resources
- Disclosures and conclusion
Topics Covered
- Classifications of glioblastoma
- Isocitrate dehydrogenase 1 mutation as the fundamental mutation in malignant glioma
- The genetic mechanism of telomere maintenance in gliomas
- Molecular subclassifcation of gliomas
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Yan, H. (2015, December 31). The genetics of glioblastoma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/FWJO6705.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Hai Yan has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello and welcome
to this talk
entitled
The Genetics of Glioblastoma
as part
of the Henry Stewart Talks
on the genetics of cancers.
My name is Dr. Hai Yan.
I am the Henry Friedman
Professor of Neuro Oncology
at Duke University
where I reside as a member
of the Department of Pathology
under Preston Robert Tisch
Brain Tumor Center.
0:27
It is my privilege
to discuss this content matter
with you today
that honors the work
of people before me
such as doctors Henry Friedman,
Darell Bigner, Bert Vogelstein
and many other
major contributors
to the field
of brain cancer research.
Naturally, I will also include
some summaries
of some of the work
I have contributed
to this important field.
This work outlines the approach
many scientists take
to making further discoveries
for aid in understanding
and the treatment of what is
a terribly deadly disease.
Let's get started.
1:07
I will break this talk down
into three sections
that go through
and involving depths of detail
into the genetics
of glioblastoma.
While the majority of this talk
will highlight the most updated,
presented work in the field,
I will also spend some time
providing a brief summary
of glioma and the hierarchy
by which we classified them.
I will then explain
to the extent
if possible how and why
the use of genetics
impacts the brain cancer
research and treatment.
This field is a critically
important work
to solving the confused cells,
rogue in their behavior
as tumors
and deadly
in their impact on people.
Lastly, I attempt to capture
just how we use genomic research
by using
some compounding stories
along the way.
The featured is that
of isocitrate dehydrogenase
better referred to as IDH.
A curious insight into
how one genomic finding
can unpack a wealth
of knowledge about
the mischievous inner workings
of cancer cells.
Finally, I'd like
to share with you
the very cutting-edge
of genomic research
by discussing a mutation
we discovered
just two years ago called TERT.
I hope you enjoy
the discussion.
Now let's begin.